Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875867 | 0.90 | TP53 (0.32) | TP53PIK3CAATAD2 | |
| SCHEMBL25875757 | 0.88 | SHMT2 (0.31) | PDE2A | |
| SCHEMBL25876241 | 0.88 | MEN1 (0.31) | KMT2A | |
| SCHEMBL25876281 | 0.88 | PDE1A (0.34) | TP53ALDH1A1HSD17B10KMT2A | |
| SCHEMBL25876137 | 0.87 | PIK3CA (0.35) | PIK3CA | |
| SCHEMBL25875947 | 0.87 | MEN1 (0.37) | TP53ALDH1A1HSD17B10KMT2APIK3CA | |
| SCHEMBL25876258 | 0.85 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL25876085 | 0.84 | MERTK (0.33) | — | |
| SCHEMBL25876305 | 0.84 | PIK3CA (0.39) | PDE2APIK3CA | |
| SCHEMBL25875975 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | TP53 840/4885PDE2A 1000/4885KDM4E 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.